These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36460881)
1. Role of NKT cells in cancer immunotherapy-from bench to bed. Bayatipoor H; Mehdizadeh S; Jafarpour R; Shojaei Z; Pashangzadeh S; Motallebnezhad M Med Oncol; 2022 Dec; 40(1):29. PubMed ID: 36460881 [TBL] [Abstract][Full Text] [Related]
2. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410 [TBL] [Abstract][Full Text] [Related]
3. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers. Singh AK; Rhost S; Löfbom L; Cardell SL Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185 [TBL] [Abstract][Full Text] [Related]
4. Application of natural killer T cells in antitumor immunotherapy. Hong C; Park SH Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797 [TBL] [Abstract][Full Text] [Related]
5. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. East JE; Sun W; Webb TJ J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308 [TBL] [Abstract][Full Text] [Related]
6. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen. Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017 [TBL] [Abstract][Full Text] [Related]
9. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262 [TBL] [Abstract][Full Text] [Related]
10. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. Hung JT; Huang JR; Yu AL J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781 [TBL] [Abstract][Full Text] [Related]
11. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903 [TBL] [Abstract][Full Text] [Related]
12. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Van Kaer L Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263 [TBL] [Abstract][Full Text] [Related]
13. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129 [TBL] [Abstract][Full Text] [Related]
14. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815 [TBL] [Abstract][Full Text] [Related]
15. The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions. Macho-Fernandez E; Brigl M Front Immunol; 2015; 6():362. PubMed ID: 26284062 [TBL] [Abstract][Full Text] [Related]
18. Regulation of immune responses by CD1d-restricted natural killer T cells. Van Kaer L Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656 [TBL] [Abstract][Full Text] [Related]
19. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma. Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370 [TBL] [Abstract][Full Text] [Related]
20. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]